Answers are grounded in this paper and cite their sources.
Background. Throughout the 2014-2015 Ebola outbreak in West Africa, major gaps were exposed in the availability of validated rapid diagnostic platforms, protective vaccines, and effective therapeutic agents. These gaps potentiated the development of prototype rapid lateral flow immunodiagnostic (LFI) assays that are true point-of-contact platforms, for the detection of active Ebola infections in small blood samples.
No takes yet. Share an insight, caveat, or question.
Boisen et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: